Explore the vast range of titles available.

Non-small cell lung cancer (NSCLC) is a life-threatening cancer associated with a higher mortality rate. Despite promising results shown by combination therapies, there remains a need for efficient drug delivery materials capable of combining various drugs, imaging agents, and targeting agents to enhance treatment efficacy. In this study, we present the synthesis of novel core-shell hollow mesoporous silica nanoparticles (@MSN) with bimodal porosity and a large surface area (694 m2/g) to facilitate targeted drug delivery for NSCLC treatment. The hollow core-shell structure enables the loading of a substantial quantity of the pemetrexed drug, up to 839 µg/mg, with a sustained release of 20% within 48 h. The MSN is surface functionalised with amino and carboxyl groups to accommodate an imaging agent and facilitate the attachment of the targeting drug bevacizumab. These particles exhibit rapid uptake by both A549 and PC-9 cells. Moreover, the targeting by bevacizumab leads to higher cytotoxicity within 48 h and induces apoptosis more effectively than the non-functionalised samples. As a versatile drug delivery platform, the hollow core-shell MSN demonstrated in this study holds great potential for various drug delivery applications.

Lung cancer is one of the most common cancers, affecting more than 2.1 million people across the globe every year. A very high occurrence and mortality rate of lung cancer have prompted active research in this area with both conventional and novel forms of therapies including the use of nanomaterials based drug delivery agents. Specifically, the unique physico-chemical and biological properties of porous nanomaterials have gained significant momentum as drug delivery agents for delivering a combination of drugs or merging diagnosis with targeted therapy for cancer treatment. This review focuses on the emergence of nano-porous materials for drug delivery in lung cancer. The review analyses the currently used nanoporous materials, including inorganic, organic and hybrid porous materials for delivering drugs for various types of therapies, including chemo, radio and phototherapy. It also analyses the selected research on stimuli-responsive nanoporous materials for drug delivery in lung cancer before summarizing the various findings and projecting the future of emerging trends. This review provides a strong foundation for the current status of the research on nanoporous materials, their limitations and the potential for improving their design to overcome the unique challenges of delivering drugs for the treatment of lung cancer.

Skin cancer has emerged as one of the leading types of cancers in the world, causing a high impact on the global burden of health and the economy. Basal cell and squamous cell carcinoma are the localized forms of skin cancer with a high prevalence and can be treated with a high success rate. However, melanoma, a rare type of skin cancer with a high mortality rate, can metastasize and invade other parts of the body. Various skin cancer treatment approaches have been developed and advanced from localized to systemic treatment over the years to improve the low success rate associated with skin cancer, especially metastatic melanoma. The systemic treatment of skin cancer is highly benefitted by drug delivery systems (DDS) designed to function with much higher specificity and lower side effects than the direct treatment with drugs. While many nanomaterials based DDS have been developed in the past few years to take advantage of the small size and high functionality of nanomaterials, silica-based nanomaterials have recently emerged as the flexible DDS with a high biocompatibility, good clearance, a high drug loading capacity, and versatility to attach several drugs and targeting agents to its surface. In this review, recent progress in the treatment of melanoma using silica-based nanomaterials and their hybrids is discussed, highlighting the versatility and potential of these emerging nanomaterials as the DDS for delivering various molecules, including drugs and immunotherapy agents, peptides, and radio- and photo-active agents. The review also introduces various therapies available for the treatment of melanoma, including surgery, chemotherapy, targeted therapy, phototherapy, and immunotherapy and discusses the improvement in these therapies based on silica-based DDS. The review also highlights the role of silica nanomaterials and their hybrids in delivering combination therapy and the advantages of silica nanohybrids over pure silica-based DDS. Finally, we summarize the present status of silica-based nanomaterials in melanoma treatment and the current challenges that have to be solved for the clinical translation of these materials as DDS.